BMC Endocr
GLP-1 / GIP Programs (Semaglutide or Tirzepatide) Program-based medications sourced from licensed U.S
Studies show these medications: Lower total cholesterol, LDL cholesterol, and triglyceride levels 10 Reduce small- and medium-sized LDL particles, which are particularly harmful 10 Promote cholesterol efflux from cells through increased ABCA1 expression 11 Liraglutide and taspoglutide demonstrate exceptional cholesterol-lowering effects, especially on total cholesterol and triglycerides 10
That way, you can benefit from the wanted effects of your GLP-1 and minimize the unwanted ones
Variants in FTO (the fat-mass and obesity-associated gene), GLP1R (the receptor every GLP-1 compound targets), MC4R (central to satiety and energy balance), and TCF7L2 (tied to glucose homeostasis) describe your baseline metabolic terrain
GLP-1 RAs have pleiotropic actions, with intervention on multiple regulation mechanisms